ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation

A. F. Alghanem1, A. Alsmari1, H. Joharji2

1Pharmaceutical Care, King Abdulaziz Medical City, Riyadh, Saudi Arabia, 2Pharmaceutical Care, King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia

Meeting: 2022 American Transplant Congress

Abstract number: 1459

Keywords: Calcineurin, Liver, Pediatric, Weight

Topic: Clinical Science » Liver » 61 - Liver: Pediatrics

Session Information

Session Name: Liver: Pediatrics

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based dose regimens required to achieve tacrolimus therapeutic target early post-liver-transplant as well as identify the factors affecting time needed to achieve therapeutic target to determine dosing regimen that can promptly achieve the target

*Methods: Ongoing multi-center retrospective study IRB was granted from 2 transplant centers. Patients included in the study if age < 18 years, underwent liver transplantation, and were on tacrolimus therapy. Tacrolimus was started with a fixed dose of 0.5 mg every 12 hours adjusted based on tacrolimus level to achieve therapeutic target level (7-12 ng/ml). Doses adjusted for body weight and serum levels were analyzed daily for the first two weeks post-transplant[Aa1] . Demographic variables and other patient’s specific factors known to affect dose requirements such as donor status, concurrent immunosuppressants, surrogate metabolism marker; concentration to dose ratio (C0/D ratio), surgery, and feeding details were collected. The primary outcome was to describe tacrolimus daily dose requirement needed to achieve therapeutic target in the first 2 weeks post-transplant. The secondary outcome is to identify factors affecting time needed to reach therapeutic tacrolimus level within first 2 weeks post-transplant

*Results: So far, 45 patients included in study 20 (44%) were female, mean age 4.29±4.42 years. The most common indication for liver transplantation were metabolic diseases (70%). Majority of patients (60% ) started on tacrolimus with a dose of < 0.1mg/kg/day mean of 0.07 ± 0.05 mg/kg/day. By the day that those patients were on target level only 30% remain on this dose range while 70% maintained on doses ³ 0.1mg/kg/day and, by day 14 this percentage further increased to 83% with a mean dose of 0.24 ±0.18 mg/kg/day. Eighty-two percent reach therapeutic target during the first 2 weeks. The average time needed to reach therapeutic is 5.92 ±2.55 days. When evaluating factors affecting time needed to reach the therapeutic level, C0/D ratio was significantly higher in patients reaching target level within 7 days compared to those who reach later in > 7 days p = 0.0020. Additionally, patients on interacting medications like caspofungin require significantly longer time reach therapeutic range when compared to those who are not p = 0.046

*Conclusions: Dose requirements appear to be higher than the usual starting tacrolimus dose in pediatric liver transplants during early phase post-transplantation. Multiple factors could affect the time needed to reach therapeutic range including tacrolimus metabolism and interacting medications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Alghanem AF, Alsmari A, Joharji H. Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-different-initial-tacrolimus-dosing-regimens-in-pediatric-post-liver-transplantation/. Accessed May 18, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences